SION (Sionna Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SION officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | Peter A. Thompson | Director | Sell | — | — |
| 2026-07-09 | ORBIMED ADVISORS LLC | Director | Sell | — | — |
| 2026-07-07 | Jennifer Fitzpatrick | Chief Legal Officer | MIXED | — | — |
| 2026-07-02 | Peter A. Thompson | Director | Sell | — | — |
| 2026-07-02 | ORBIMED ADVISORS LLC | Director | Sell | — | — |
| 2026-06-18 | Bruce Booth | Director | A | — | — |
| 2026-06-18 | Joshua Resnick | Director | A | — | — |
| 2026-06-18 | Joanne L. Viney | Director | A | — | — |
| 2026-06-18 | Peter A. Thompson | Director | A | — | — |
| 2026-06-18 | Marcella K. Ruddy | Director | A | — | — |
| 2026-06-18 | Laurie Stelzer | Director | A | — | — |
| 2026-06-18 | Harold Edward Fleming | Director | A | — | — |
| 2026-06-18 | RA CAPITAL MANAGEMENT, L.P. | Director | A | — | — |
| 2026-06-18 | Paul J Clancy | Director | A | — | — |
| 2026-05-29 | OrbiMed Capital GP VIII LLC | Director | Sell | — | — |
| 2026-05-29 | Peter A. Thompson | Director | Sell | — | — |
| 2026-05-11 | Peter A. Thompson | Director | Sell | — | — |
| 2026-05-11 | ORBIMED ADVISORS LLC | Director | Sell | — | — |
| 2026-04-21 | Peter A. Thompson | Director | Sell | — | — |
| 2026-04-21 | ORBIMED ADVISORS LLC | Director | Sell | — | — |
| 2026-04-16 | ORBIMED ADVISORS LLC | Director | Sell | — | — |
| 2026-04-16 | Peter A. Thompson | Director | Sell | — | — |
| 2026-03-06 | Jennifer Fitzpatrick | Chief Legal Officer | MIXED | — | — |
| 2026-02-04 | Peter A. Thompson | Director | Sell | — | — |
| 2026-02-04 | OrbiMed Capital GP VIII LLC | Director | Sell | — | — |
| 2026-01-26 | JAMES G COULTER | 10%+ Owner | Sell | — | — |
| 2026-01-06 | Caroline Stark Beer | Chief Business Officer | A | — | — |
| 2026-01-06 | Jennifer Fitzpatrick | Chief Legal Officer | A | — | — |
| 2026-01-06 | Elena Ridloff | CFO | A | — | — |
| 2026-01-06 | Michael Cloonan | President & CEO | A | — | — |
| 2026-01-06 | Charlotte McKee | Chief Medical Officer | A | — | — |
| 2025-12-29 | Peter A. Thompson | Director | Sell | — | — |
| 2025-12-29 | ORBIMED ADVISORS LLC | Director | Sell | — | — |
| 2025-12-19 | OrbiMed Capital GP VIII LLC | Director | Sell | — | — |
| 2025-12-19 | Peter A. Thompson | Director | Sell | — | — |
| 2025-12-09 | Jennifer Fitzpatrick | Chief Legal Officer | MIXED | — | — |
| 2025-11-26 | Peter A. Thompson | Director | Sell | — | — |
| 2025-11-26 | OrbiMed Capital GP VIII LLC | Director | Sell | — | — |
| 2025-11-24 | RA CAPITAL MANAGEMENT, L.P. | Director | Sell | — | — |
| 2025-11-19 | Peter Kolchinsky | Director | Sell | — | — |
| 2025-10-28 | RA Capital Nexus Fund III, L.P. | Director | Sell | — | — |
| 2025-10-22 | Michael Cloonan | President & CEO | MIXED | — | — |
| 2025-10-21 | Bruce Booth | Director | Sell | — | — |
| 2025-10-20 | Bruce Booth | Director | Sell | — | — |
| 2025-10-17 | Michael Cloonan | President & CEO | MIXED | — | — |
| 2025-10-15 | Bruce Booth | Director | Sell | — | — |
| 2025-10-07 | Bruce Booth | Director | Sell | — | — |
| 2025-10-03 | Caroline Stark Beer | Chief Business Officer | A | — | — |
| 2025-10-01 | Bruce Booth | Director | Sell | — | — |
| 2025-09-30 | Michael Cloonan | President & CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 6,909,249 | — |
| — | Director | 6,899,079 | — |
| — | 10%+ Owner | 6,744,962 | — |
| — | 10%+ Owner | 6,494,962 | — |
| — | 10%+ Owner | 3,694,020 | — |
| — | Director | 2,671,721 | — |
| — | Director | 2,469,959 | — |
| — | Director | 2,469,959 | — |
| — | Director | 2,360,156 | — |
| — | Director | 661,019 | — |
| — | President & CEO | 547,343 | — |
| — | CFO | 47,368 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SION quote page; the site-wide leaderboard is on the insider transactions hub.